Tech Company Financing Transactions
Eccogene Funding Round
On 6/12/2023, Eccogene raised $25.2 million in Series B funding from New Alliance Capital, Delos Capital and Elikon Venture.
Transaction Overview
Company Name
Announced On
6/12/2023
Transaction Type
Venture Equity
Amount
$25,160,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for the development of its clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRß full agonist for NASH and lipid disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Room 402A, No. 326 Edison Road Zhangjiang Hi-Tech Park, Pudo
Shanghai, Undisclosed
CN
Shanghai, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Overview
Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases. Eccogene is specialized in disease biology, medicinal chemistry, and translational science to advance its novel and differentiated pipeline of drugs to address the unmet medical needs for metabolic and immune-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jingye Zhou
Co-Founder
Jianfeng Xu
Browse more venture capital transactions:
Prev: 6/12/2023: Hyper venture capital transaction
Next: 6/12/2023: CloudZero venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs